NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer and viral infectious diseases. NK cells are the body's first line of defense due to their innate ability to seek and destroy abnormal cells, such as cancer or virally infected cells, without prior exposure or activation by other support molecules required to train and activate adaptive immune cells such as T-Cells. Co. holds the exclusive right to commercialize activated NK cells, a commercially viable natural killer cell line, and a range of genetically modified derivatives capable of killing cancer and virally infected cells.
|
Free NK Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 91st percentile
(ranked higher than approx. 91% of all stocks covered)
Analysts' Target Price: NK Stock Forecast Based on Zacks ABR data; powered by Xignite |